{"id":43458,"date":"2025-10-15T17:18:07","date_gmt":"2025-10-15T09:18:07","guid":{"rendered":"https:\/\/flcube.com\/?p=43458"},"modified":"2025-10-15T17:18:07","modified_gmt":"2025-10-15T09:18:07","slug":"zennova-rapafusyn-forge-alliance-to-accelerate-non%e2%80%91degrading-molecular-glue-therapies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43458","title":{"rendered":"Zennova &amp; Rapafusyn Forge Alliance to Accelerate Non\u2011Degrading Molecular Glue Therapies"},"content":{"rendered":"\n<p><strong>Zennova Pharmaceutical<\/strong> announced today a strategic partnership with U.S.\u2011based biotech <strong>Rapafusyn Pharmaceuticals<\/strong> to jointly develop next\u2011generation non\u2011degrading molecular glue medicines. The collaboration will leverage Zennova\u2019s proprietary <strong>BioCarier<\/strong> delivery platform to expedite the clinical development of Rapafusyn\u2019s lead candidate <strong>RAP\u20118020<\/strong> and additional pipeline assets.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-highlights\">Partnership Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Collaborators<\/strong><\/td><td>Zennova &amp; Rapafusyn Pharmaceuticals<\/td><\/tr><tr><td><strong>Objective<\/strong><\/td><td>Accelerate development of RapaGlue\u2011based therapeutics using BioCarier technology<\/td><\/tr><tr><td><strong>Key Assets<\/strong><\/td><td>RAP\u20118020 (lead candidate), other RapaGlue candidates<\/td><\/tr><tr><td><strong>Technology Synergy<\/strong><\/td><td>BioCarier enhances oral bioavailability of BCS\u202fIV &amp; &gt;\u202f1,000\u202fDa molecules; Rapafusyn\u2019s DEL\u2011derived FKBP12\u2011binding macrocycles target \u201cundruggable\u201d proteins<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-zennova-s-biocarier-platform\">Zennova\u2019s BioCarier Platform<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patent\u2011Protected<\/strong> delivery system optimized for low\u2011solubility, high\u2011molecular\u2011weight drugs.<\/li>\n\n\n\n<li>Proven ability to <strong>boost oral absorption<\/strong> of BCS\u202fIV compounds and large biologics.<\/li>\n\n\n\n<li>Designed to overcome formulation challenges that historically limit clinical translation.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-rapafusyn-s-rapaglue-modality\">Rapafusyn\u2019s RapaGlue Modality<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecular glue<\/strong> technology that coerces protein\u2011protein interactions, enabling degradation of previously \u201cundruggable\u201d targets such as transcription factors and transmembrane proteins.<\/li>\n\n\n\n<li>Built on <strong>large DNA\u2011encoded libraries (DELs)<\/strong> of rationally designed FKBP12\u2011binding macrocyclic peptides.<\/li>\n\n\n\n<li>Expansive pipeline across oncology, immunology, nephrology, and pain therapeutics.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-combined-strategy\">Combined Strategy<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Stage<\/th><th>Action<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Discovery &amp; Lead Optimization<\/strong><\/td><td>Rapafusyn\u2019s RapaGlue candidates<\/td><td>Target novel protein classes<\/td><\/tr><tr><td><strong>Formulation &amp; Delivery<\/strong><\/td><td>Zennova\u2019s BioCarier<\/td><td>Enhance oral bioavailability, reduce dosing frequency<\/td><\/tr><tr><td><strong>Preclinical &amp; Clinical Development<\/strong><\/td><td>Joint effort<\/td><td>Accelerate regulatory milestones, reduce attrition<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h3>\n\n\n\n<p>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zennova Pharmaceutical announced today a strategic partnership with U.S.\u2011based biotech Rapafusyn Pharmaceuticals to jointly develop&#8230;<\/p>\n","protected":false},"author":1,"featured_media":43460,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4320,70,2504],"class_list":["post-43458","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-rapafusyn-pharmaceuticals","tag-tpd","tag-zennova-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Zennova &amp; Rapafusyn Forge Alliance to Accelerate Non\u2011Degrading Molecular Glue Therapies - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Zennova Pharmaceutical announced today a strategic partnership with U.S.\u2011based biotech Rapafusyn Pharmaceuticals to jointly develop next\u2011generation non\u2011degrading molecular glue medicines. The collaboration will leverage Zennova\u2019s proprietary BioCarier delivery platform to expedite the clinical development of Rapafusyn\u2019s lead candidate RAP\u20118020 and additional pipeline assets.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43458\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zennova &amp; Rapafusyn Forge Alliance to Accelerate Non\u2011Degrading Molecular Glue Therapies\" \/>\n<meta property=\"og:description\" content=\"Zennova Pharmaceutical announced today a strategic partnership with U.S.\u2011based biotech Rapafusyn Pharmaceuticals to jointly develop next\u2011generation non\u2011degrading molecular glue medicines. The collaboration will leverage Zennova\u2019s proprietary BioCarier delivery platform to expedite the clinical development of Rapafusyn\u2019s lead candidate RAP\u20118020 and additional pipeline assets.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43458\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-15T09:18:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1514.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43458#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43458\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zennova &amp; Rapafusyn Forge Alliance to Accelerate Non\u2011Degrading Molecular Glue Therapies\",\"datePublished\":\"2025-10-15T09:18:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43458\"},\"wordCount\":261,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43458#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1514.webp\",\"keywords\":[\"Rapafusyn Pharmaceuticals\",\"TPD\",\"Zennova Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43458#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43458\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43458\",\"name\":\"Zennova &amp; Rapafusyn Forge Alliance to Accelerate Non\u2011Degrading Molecular Glue Therapies - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43458#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43458#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1514.webp\",\"datePublished\":\"2025-10-15T09:18:07+00:00\",\"description\":\"Zennova Pharmaceutical announced today a strategic partnership with U.S.\u2011based biotech Rapafusyn Pharmaceuticals to jointly develop next\u2011generation non\u2011degrading molecular glue medicines. The collaboration will leverage Zennova\u2019s proprietary BioCarier delivery platform to expedite the clinical development of Rapafusyn\u2019s lead candidate RAP\u20118020 and additional pipeline assets.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43458#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43458\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43458#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1514.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1514.webp\",\"width\":1080,\"height\":608,\"caption\":\"Zennova & Rapafusyn Forge Alliance to Accelerate Non\u2011Degrading Molecular Glue Therapies\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43458#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zennova &amp; Rapafusyn Forge Alliance to Accelerate Non\u2011Degrading Molecular Glue Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zennova &amp; Rapafusyn Forge Alliance to Accelerate Non\u2011Degrading Molecular Glue Therapies - Insight, China&#039;s Pharmaceutical Industry","description":"Zennova Pharmaceutical announced today a strategic partnership with U.S.\u2011based biotech Rapafusyn Pharmaceuticals to jointly develop next\u2011generation non\u2011degrading molecular glue medicines. The collaboration will leverage Zennova\u2019s proprietary BioCarier delivery platform to expedite the clinical development of Rapafusyn\u2019s lead candidate RAP\u20118020 and additional pipeline assets.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43458","og_locale":"en_US","og_type":"article","og_title":"Zennova &amp; Rapafusyn Forge Alliance to Accelerate Non\u2011Degrading Molecular Glue Therapies","og_description":"Zennova Pharmaceutical announced today a strategic partnership with U.S.\u2011based biotech Rapafusyn Pharmaceuticals to jointly develop next\u2011generation non\u2011degrading molecular glue medicines. The collaboration will leverage Zennova\u2019s proprietary BioCarier delivery platform to expedite the clinical development of Rapafusyn\u2019s lead candidate RAP\u20118020 and additional pipeline assets.","og_url":"https:\/\/flcube.com\/?p=43458","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-15T09:18:07+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1514.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43458#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43458"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zennova &amp; Rapafusyn Forge Alliance to Accelerate Non\u2011Degrading Molecular Glue Therapies","datePublished":"2025-10-15T09:18:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43458"},"wordCount":261,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43458#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1514.webp","keywords":["Rapafusyn Pharmaceuticals","TPD","Zennova Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43458#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43458","url":"https:\/\/flcube.com\/?p=43458","name":"Zennova &amp; Rapafusyn Forge Alliance to Accelerate Non\u2011Degrading Molecular Glue Therapies - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43458#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43458#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1514.webp","datePublished":"2025-10-15T09:18:07+00:00","description":"Zennova Pharmaceutical announced today a strategic partnership with U.S.\u2011based biotech Rapafusyn Pharmaceuticals to jointly develop next\u2011generation non\u2011degrading molecular glue medicines. The collaboration will leverage Zennova\u2019s proprietary BioCarier delivery platform to expedite the clinical development of Rapafusyn\u2019s lead candidate RAP\u20118020 and additional pipeline assets.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43458#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43458"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43458#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1514.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1514.webp","width":1080,"height":608,"caption":"Zennova & Rapafusyn Forge Alliance to Accelerate Non\u2011Degrading Molecular Glue Therapies"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43458#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zennova &amp; Rapafusyn Forge Alliance to Accelerate Non\u2011Degrading Molecular Glue Therapies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1514.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43458","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43458"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43458\/revisions"}],"predecessor-version":[{"id":43461,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43458\/revisions\/43461"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43460"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43458"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43458"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43458"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}